林业发展局核准用于非诊断性管理血糖的CGMs,研究显示结果好坏参半。 FDA approves CGMs for non-diabetics to manage blood sugar, with mixed results shown in studies.

连续的葡萄糖监测器(CGMs)通过跟踪血糖水平,改变了糖尿病护理。 Continuous glucose monitors (CGMs) have transformed diabetes care by tracking blood sugar levels. 2024年3月,FDA批准了非糖尿病患者使用CGM,旨在帮助控制血糖并可能降低糖尿病风险. In March 2024, the FDA approved CGMs for non-diabetic individuals, aiming to help manage blood sugar and potentially reduce diabetes risk. 然而,研究表明,结果好坏参半;虽然一些使用者的血糖水平和体重下降情况有所改善,但其他使用者却没有看到任何重大好处。 However, studies show mixed results; while some users experienced improved blood sugar levels and weight loss, others saw no significant benefits. 专家们提出了不同的结果,适当的指导对有效使用至关重要。 Experts suggest individual outcomes vary, and proper guidance is crucial for effective use.